Providing Market Intelligence for 40 Years

In The News

Smart thermostats are tough sell, but ComEd hopes rebates boost interest

A study released this month by Parks Associates found only 18 percent of consumers would buy a smart thermostat at $250, but offering a $100 rebate more than doubled the pool of interested buyers.

"The market for smart thermostats is still in the early adopter phase," said Tom Kerber, director of internet of things strategy for Parks Associates, a Texas-based consumer technology research and consulting company. "To move beyond early adopters, they have to offer products at a lower price point."

Kerber said prices for the first-generation smart thermostats started at about $400 but have dropped to about $250 for Nest and other leading products. He said breaking through the $150 price point opens it up to a broader market.

From the article "Smart thermostats are tough sell, but ComEd hopes rebates boost interest" by Robert Channick.

Previously In The News

AT&T kills Plenti loyalty program but touts ongoing Thanks campaign

Parks Associates reported last year that 60% of respondents in a survey valued a rewards program for being a loyal customers, third only to the ability to roll over unused data (66%) and free access t...

One in five US subscribers now ‘dissatisfied’ with pay TV service

Some 20% of US pay TV subscribers are now dissatisfied with their pay TV service, according to research from Parks Associates. The future represents a 100% increase since 2013, according to Parks....

AT&T gooses $45 prepaid plan with cheaper iPhones

And, as a recent report from Parks Associates noted, consumers are increasingly drawn to the simplified pricing offers in prepaid. The firm said that “currently postpaid carriers are starting to explo...

Morning Read: Pharma Changes Afoot As Valeant Courts A New CEO And Novartis U.S. Head Exits

Less than half of caregivers with a smartphone use apps aimed at caregivers, according to a report by Parks Associates. — MobiHealthNews From the article "Morning Read: Pharma Changes Afoot As Vale...